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We have read with interest the letter written by Dr. Taya-
saheb Patil about our article on “Prehypertension in young
female, where they stand?”
The comments made in their letter to Editor are valid and
welcome and contribute to our understanding of the
phenomenon. However, the scope of our study as mentioned
in methods is restricted to studying blood pressure response
to tread mill test among prehypertensive female subjects
along with other phenotypes. We chose this parameterFig. 1 e Individual and pooled (95% Confidence Interval, 95% CI
curve (AUC) of pregnancy-associated plasma protein A (PAPP-Alooking at the scope of study and feasibility. By no means it is
intended to replace in any manner other well-known risk
factors. At best this could be one more variable that may be
used to stratify the population further based on their response
to stress like tread mill.
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DOI of original article: http://dx.doi.org/10.1016/j.ihj.2012.10.004Pregnancy-associated plasma protein A (PAPP-A) for the early
diagnosis of myocardial infarction: More doubts than
certaintiesWe readwith interest the recent article of Gururajan et al, who
concluded that pregnancy-associated plasma protein A (PAPP-
A) seems to be a promising biomarker for identification and
risk stratification for patients with ischemic heart disease.1 In
particular, this promising biomarker exhibited an area under
the Receiver Operator Characteristics (ROC) curve (AUC) that
was even higher than that of troponin I (i.e., 0.904 versus 0.765)
in patients admitted to emergency care unit.
PAPP-A is a high-molecular-mass glycoprotein, which is
mainly synthesized by the syncytiotrophoblast and has orig-
inally been proposed for the screening of Down syndrome. In
2001, however, Bayes-Genis et al first suggested that PAPP-A
may be a promising candidate biomarker of ischemic heart
disease, reporting an AUC of 0.94 for discriminating patientswith acute myocardial infarction (AMI) from those without
ischemic heart injury.2 Since major controversy still exists on
the clinical usefulness of PAPP-A for the early diagnosis of
AMI, we carried out an electronic search on PubMed, Thomson
and Scopus to retrieve scientific articles that have assessed
PAPP-A in the diagnostics of ischemia heart disease by using
the keywords “myocardial infarction” or “ischaemic heart
disease”, “diagnosis”, “troponin”, and “PAPP-A” or “preg-
nancy-associated plasma protein A”. The references were
systematically assessed for quality by two authors (GL and GC)
according to the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS) checklist criteria, and searched for addi-
tional studies on this topic. After reading of abstract and text,
only those studies comparing the diagnostic performance of) Area Under the Receiver Operator Characteristics (ROC)
) for early diagnosis of ischemic heart disease.
